Effect of PSC 833 on the efficacy of doxorubicin in vitro in a medullary thyroid carcinoma cell line

Anticancer Research

Volumn 18, Issue 4 C, 1998, Pages 2953-2956

  Massart, C ^a   Gibassier, J ^a   Denais, A ^a   Genetet, N ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Doxorubicin; Medullary thyroid carcinoma; Multidrug resistance; PSC 833

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLUTATHIONE; LACTATE DEHYDROGENASE; NEUTRAL RED; VALSPODAR;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MONOLAYER CULTURE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, MEDULLARY; CYCLOSPORINS; DOXORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0031812462     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Schlumberger M, Gardet P, De Vataire F, Sarrazin D, Travagli JP and Parmentier C: External radiotherapy and chemotherapy in MTC patients. In: Calmettes C, Guliana JM, eds. Medullary Thyroid carcinoma. Colloque Inserm/John Libbey Eurotext Ld, 1991, pp 213-220.
2. Chin KV, Pastan I and Gottesman MM: Function and regulation of the multidrug resistance gene. Adv Cancer Res 60: 157-180, 1993.
3. Ford JM and Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990.
4. Tsuruo T. Mechanism of multidrug resistance and implications for therapy: Jpn J Cancer Res 79: 285-296, 1988.
5. Leong SS, Horoszewicz JS, Shimaoka K, Friedman M, Kawinski E, Song MJ, Zeigel R, Chu TM, Baylin S and Mirand EA: A new cell line for study of human medullary thyroid carcinoma. In: Andreoli M., Monaco F, Robbins J, eds. Advances in Thyroid Neoplasia. Rome: Fied Educational Italia, pp 95-108, 1981.
6. Massart C, Gibassier J, Lucas C, Le Gall, Giscard-Dartevelle S, Bourdiniere J, Moukhtar MS and Nicol M: Hormonal study of a mixed follicular and medullary carcinoma. J Mol Endocrinol 11: 59-67, 1993.
7. Larsson R and Nygren P: Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in the human medullary thyroid carcinoma TT cell line not expressing the 170 kDa P-glycoprotein: Cancer Lett 54: 125-131, 1990.
8. Massart C, Gibassier J, Lucas C, Pourquier P and Robert J: Expression du gene MDR1 dans 5 lignees humaines de cancer medullaire de la thyroide et reversion de la resistance a la doxorubicine par la ciclosporine A et le verapamil. Bull Cancer 83: 39 45, 1996.
9. Massart C, Gibassier J, Raoul ML, Pourquier P, Robert J and Lucas C: Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line. Anti-Cancer Drugs 6: 135-146, 1995.
10. Yang KP, Liang YF and Samaan NA: Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with overexpression of mdr1 gene and low proliferation fraction. Anticancer Res 11: 1065-1068, 1991.
11. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981.
12. Tsuruo T, Iida H, Noriji M, Tsukagoshi S and Sakurai Y: Circumvention of vincristine and adriamycine resistance in vitro and in vivo by calcium influx blockers. Cancer Res 43: 2905-2910, 1983.
13. Slater LM, Sweet P, Stupecky M and Gupta S: Cyclosporin A reverses vincristine and daunorubicin resistance in acute leukemia in vitro. J Clin Invest 77: 1405-1408, 1986.
14. Cros S, Guibaud N, Berlion M, Dunn T, Regnier G, Dhainaut A, Atassi G and Bizarri JP: In vivo evidence of complete circumvention of vincristine resistance by a new triaziaminopiperidine derivative S9788 in P388/VCR leukemia model. Cancer Chemother Pharmacol 30: 491-494, 1992.
15. Massart C, Gibassier J, Raoul M, Maugendre S, Darcel F and Lucas C. Effect ot S9788 on the efficiency of doxorubicin.in vivo and in vitro in medullary thyroid carcinoma xenograft: Anti-cancer Drugs 7: 321-330, 1996.
16. Twentyman PR: A possible role for cyclosporins in cancer chemotherapy. Anticancer Res 8: 985-994, 1988.
17. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A. Bollinger P and Loor F: In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51-4226-4233, 1991.
18. Boesch D, Muller K, Pourtier-Manzanedo A and Loor F: Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosupressive cyclosporin derivative. Exp Cell Res 196: 26-32, 1991.
19. Gaveriaux C, Boesch D, Jachez B, Bollinger P, Payne T and Loor F: SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifer. J Cell Pharmacol 2: 225-234, 1991.
20. Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA and Hiestand PC: Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 57: 433-438, 1992.
21. Ehrlich PH, Moustafa ZA, Archinal-Mattheis AE, Newman MJ, Bair KW and Cohen D: The reversal of multidrug resistance in multicellular tumor spheroids by SDZ PSC 833. Anticancer Res 17: 129-134, 1997.
22. Massart C, Le Tellier C, Lucas C, Gibassier J, Leclech G and Nicol M: Effects of cisplatin on human thyrocytes in monolayer and follicle culture. J Mol Endocrinol 8: 243-248, 1992.
23. Ratanasavanh D, Baffet G, Latinier MF, Rissel M and Guillouzo A. Use of hepatocyte co-cultures in the assessment of drug toxicity from chronic exposure. Xenobiotica 8: 765-771, 1988.
24. Chesne C, Clerc C, Guyomard C, Fautrel A and Guillouzo A. Evaluation of various parameters in testing drug cytotoxicity in primary hepatocyte cultures. In Goldberg AM. ed. Prog, in in vitro Tox: New Directions, New York, 1990, pp 191-196.
25. Massart C, Le Tellier C, Gibassier J, Leclech G and Nicol M. Modulation by dimethylsulfoxide of the cis-diamminedichloroplatinum-induced cytotoxicity on cultured thyrocytes. Tox in Vitro 7: 87-94, 1993.
26. Le Bot MA, Begue JM, Kernaleguen D, Robert J, Ratanasavanh D, Airiau J, Riche C and Guillouzo A. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes. Biochem Pharmacol 37: 3877-3887, 1988.
27. Fardel O, Ratanasavanh D, Loyer P, Kettere RB and Guillouzo A. Overexpression of the multidrug resistance gene product in adult rat hepatocytes during primary culture. Eur J Biochem 205: 847-852, 1992.
28. Marks DC, Belov L, Davey MW, Davey RA, Kidman AD. The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. Leukemia Res 16: 1165-1173, 1992.
29. Twentyman PR and Bleehen NM: Resistance modification by PSC-833, a novel non-immunosupresive cyclosporin A. Eur J Cancer 27: 1639-1642, 1991.
30. Watanabe T, Tsuge H, Oh-Hara T, Naito M and Tsuruo T: Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34: 235-241, 1995.
31. Friche E, Buhl Jensen P and Nissen NI: Comparison of cyclosporin A and SDZ PSC 833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Cancer Chemother Pharmacol 30: 235-237, 1992.